sur Lobe Sciences Ltd. (CVE:LOBE)
Lobe Sciences Appoints New Chief Medical Officer
On October 20, 2026, Lobe Sciences Ltd. announced the appointment of Dr. Tracy L. Goeken as Chief Medical Officer. Lobe Sciences, a clinical-stage biopharmaceutical company, focuses on therapies for neurological conditions and rare diseases. Dr. Goeken's prior experience includes serving as Chief Medical Officer at Linical, a global clinical research organization.
Dr. Frederick D. Sancilio, Chairman and CEO of Lobe Sciences, emphasized Dr. Goeken's relevant expertise in clinical development and regulatory strategy. Dr. Goeken will contribute significantly to advancing Lobe's key programs, such as L-130 for generalized anxiety disorder and S-100 for sickle cell disease.
In addition, Lobe Sciences engaged Independent Trading Group (ITG), Inc. to provide market-making services, aiming to support a fair market. The initial agreement is for C$6,000 per month, with monthly renewals.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Lobe Sciences Ltd.